Browse News
Filter News
Found 807,620 articles
-
Many promising small molecules have lost significant investment appeal as a result of lopsided incentives favoring biologics in 2022’s Inflation Reduction Act.
-
While some companies look to AI models to stop revenue leakage in business operations, experts say more fundamental issues must first be addressed.
-
NGM Bio Announces Closing of Tender Offer
4/10/2024
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an affiliate of The Column Group, LP (“TCG”), through its wholly-owned subsidiary Atlas Neon Merger Sub, Inc. (“Merger Sub”), has successfully completed the previously announced cash tender offer to acquire all outstanding shares o
-
Pfizer’s respiratory syncytial virus vaccine Abrysvo is just as effective in younger adults aged 18 to 59 years as it is in the shot’s currently approved population of 60 years of age and older.
-
A pair of biotechs burst onto the scene Tuesday, exiting stealth with $100 million in financing each and tapping executives who made their names at bluebird bio and Karuna Therapeutics.
-
After BrainStorm Cell Therapeutics withdrew its BLA in October 2023 for NurOwn, the company announced Tuesday that the FDA has agreed to the design of a Phase IIIb trial for its amyotrophic lateral sclerosis candidate under a Special Protocol Assessment.
-
With the American Association for Cancer Research’s annual conference well underway, data from vaccines and other products targeting tough-to-treat cancers have dominated the program.
-
CryoEM: Evolution and Best Practices
4/9/2024
Helix Biostructures offers a full gene-to-structure suite of cryo-EM services that focuses on both quality and fast turnaround/throughput. -
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
As part of its ongoing review, the European Medicines Agency this week is slated to examine the potential risks of suicidal ideation and self-harm associated with diabetes and weight-loss treatments.
-
Even with discounts that reach as high as 86%, Humira biosimilars are finding it difficult to take market share away from the AbbVie blockbuster, according to a new report from Samsung Bioepis.
-
Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.
-
NeuroCatch Introduces PeakSelect, Enabling a Deeper Clinical Dive into Brain Vital Signs at a Doctor's Office Near You
4/9/2024
NeuroCatch Inc., a leading medical device company that enables rapid access to an objective assessment of brain health at the point of care, announced the release of PeakSelect, an innovative software tool designed to improve clinical decision making.
-
Bayer and Google Cloud to Accelerate Development of AI-powered Healthcare Applications for Radiologists
4/9/2024
Bayer and Google Cloud announced a collaboration on the development of artificial intelligence solutions to support radiologists and ultimately better serve patients.
-
eFFECTOR Therapeutics to Participate in Upcoming April 2024 Investor Conference
4/9/2024
eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced that the Company will present at the Stifel Virtual Oncology Forum on Tuesday, April 16th at 11:30 am ET.
-
EFISHient Protein Announces Successful Development of Tilapia Cell Line
4/9/2024
EFISHient Protein, a leading Israeli FoodTech company, proudly announces the successful completion of the Tilapia cell line development.
-
Oakwood Chemical Announces Strategic Partnership with EMP Biotech GmbH
4/9/2024
Oakwood Chemical is thrilled to unveil its collaboration with EMP Biotech GmbH, a move set to streamline the oligo synthesis supply chain.
-
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
4/9/2024
YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company") today announced positive interim results from the ongoing Phase 3 clinical trial (the "Phase 3 Trial" or the "Trial") of its next-generation PIKA Rabies Vaccine.
-
Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting
4/9/2024
Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it will present new non-clinical data that highlight the combinability of nab-sirolimus and its potential for synergy to enhance anti-cancer effects and overcome resistance.
-
Alcanza Clinical Research Acquires Innovation Medical Research Center
4/9/2024
Alcanza Clinical Research, a mission-focused investigator site network, has acquired Innovation Medical Research Center, a multi-specialty clinical research center.